An interventional study of Lp(a) Screening in Atherosclerotic Cardiovascular Disease, sponsored by Amgen. Completed at 735 sites in 36 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-27.
Sponsored by Amgen · Not applicable, Interventional, and Basic science
The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold:
1,567 studies on the registry are indexed under Atherosclerosis; 264 are open to participants now.
This study's enrollment of 39,480 is above the median of 106 across 882 interventional studies indexed under Atherosclerosis.
Browse Atherosclerosis studies →Amgen is the lead sponsor of 1,015 studies on the registry; 49 are open to participants now.
Of its 245 completed or terminated interventional studies of FDA-regulated products, 159 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants with history of ASCVD with known or unknown Lp(a) values.
Other: Lp(a) Screening
Participants will provide demographic information and have a blood draw for Lp(a) levels if they are unknown.
Number of participants with elevated Lp(a) with documented history of ASCVD
Time frame: Up to approximately 2 weeks
Lp(a) Levels
Blood sampling will be performed in cases where Lp(a) values are not available at enrollment. In cases where Lp(a) values are available, data will be collected retrospectively.
Time frame: Up to approximately 2 weeks
Lp(a) Levels stratified by demographics and region
Time frame: Up to approximately 2 weeks
Showing the first 100 of 735 sites across 36 countries.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Sap, Icf, Csr
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amgen